2004

1. Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: Results of a large, multicentre phase II study

   Cancer Chemotherapy and Pharmacology, Vol. 53, Núm. 1, pp. 75-81